Findoc-cll.in/2nd_qtr_result

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED RESULTS FOR THE QUARTER ENDED : 30TH SEPTEMBER 2013.

(Rupees in '000')

S. No.

Particulars

Un -audited

Un-audited

Audited

Quarter Ended

Half Year Ended

Year Ended

30.Sep.13

30.Jun.13

30.Sep.12

30.Sep.13

30.Sep.12

31.Mar.13

PART-l

(a)Income from Operation

Gross Sales

19,712

20,712

19,157

40,424

42,410

76,818

less Excise Duty

1,261

1,398

1,264

2,659

2,811

5,282

Net Sales/Income From Operation

18,451

19,314

17,893

37,765

39,599

71,536

(b) Other Operating Income

323

Total Income from Operation

18,451

19,314

17,893

37,765

39,599

71,859

Expenditure

(a)

Consumption of Materials

5,154

6,601

7,088

11,755

13,072

21,402

(b)

Purchase of Goods Traded

1,344

1,777

1,504

3,121

3,374

5,460

(c)

(Increase)/Decrease in stock in trade

1,679

(2,224)

1,694

165

1,702

(d)

Staff Cost

6,614

6,212

6,592

12,826

13,473

25,748

(e)

Depreciation

657

655

653

1,312

1,306

2,619

(f)

Other Expenses

2,892

3,397

3,509

6,289

6,621

12,083

Total Expenditure

18,340

18,657

17,122

36,997

38,011

69,014

Profit/(Loss) from Operation Before Other Income ( 1-2)

111

657

771

768

1,588

2,845

Other Income (Loss)

299

248

350

454

775

Profit /Loss before Interest & Exceptional items (3+4)

410

708

1,019

1,118

2,042

3,620

Interest

291

405

542

696

1,079

2,021

Profit /Loss after Interest but before exceptional items (5-6)

119

303

477

422

963

1,599

Exceptional items

Profit /Loss before Tax ( 7-8)

119

303

477

422

963

1,599

Tax Expenses ( Provision for Taxation ) Current tax

297

Deffered tax

504

Net Profit/Loss after Tax (9-10)

119

303

477

422

963

798

Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears]

354,35

Reserves Excluding Revaluation Reserves

8,428

Earning per share (EPS) before extraordinary item( not Annualised)

i) Basic & Diluted

0.17

ii) Diluted

PART-ll

PARTICULARS OF SHAREHOLDING

Public shareholding

Number of Shares

2,894,901

2,904,901

2,894,901

2,904,901

Percentage of shareholding

63.33%

63.55%

63.33%

63.55%

Promoters and promoter group Shareholding

Pledged/Encumbered

Number of shares

Percentage of shares (as a % of the total shareholding of promoter and promoter group)

iii

Percentage of shares (as a% of the total share capital of the company)

Non-encumbered

Number of Shares

1,676,099

1,666,099

1,676,099

1,666,099

Percentage of shares (as a% of the total shareholding of promoter and promoter group)

36.67%

36.45%

36.67%

36.45%

Percentage of shares (as a % of the total share capital of the company)

100%

B.	INVESTORS COMPLAINTS	3 Months ended 30.09.2013
	Pending at Begining of the Quarter	NIL
	Received During the Quarter	NIL
	Disposed of During the Quarter	NIL
	Remaining at the end of the Quarter	NIL

STATEMENT OF ASSETS AND LIABILITIES			(Rupees in '000')
Particulars			As at 30.09.2013	As at 31.03.2013
Particulars			(Un-Audited)	(Audited)
A		EQUITY AND LIABILITIES
1		SHARE HOLDERS FUND
	a)	Share Capital	35,435	35,435
	b)	Reserves and Surplus	27,571	27,149
	Total		63,006	62,584
2		NON CURRENT LIABILITIES
	a)	Long term borrowing	20,578	22,554
	b)	Deffered tax liability(net)	3,604	3,604
	c)	Other long term liability	155	147
	d)	Long term Provision	-	-
	Total		24,337	26,305
3		CURRENT LIABILITIES
	a)	Short term borrowing	-	-
	b)	Trade payable	7,110	4,013
	c)	Other current liabilities	6,423	5,652
	d)	Short term provision	-	-
	Total		13,533	9,665

		Total ( 1+2+3)	100,876	98,554

B		ASSETS
1		NON CURRENT ASSETS
	a)	Fixed Assets	38,476	39,761
	b)	Non current investments	3,159	3,159
	c)	Long term loans and advances	13,543	13,543
	d)	Other Non current assets	0	599
	Total		55,178	57,062
2		CURRENT ASSETS
	a)	Inventories	17,395	18,606
	b)	Trade receivable	16,472	12,717
	c)	Cash and cash equivalents	10,331	9,384
	d)	Short term loans and advances	1,500	785
		Sub-Total of Current Assets	45,698	41,492

		Total ( 1+2 )	100,876	98,554

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on 31-10-2013
The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
Previous period figures have been regrouped wherever required.